Always agile, we reliably guide you and your molecule
through the challenging terrain of innovative drug development
with deep scientific expertise.
A siloed, serial and fragmented approach to drug development may lead to poor and delayed distribution of information causing duplicate work and even rework, particularly in early phase development where study design is subject to continuous change.
We strongly believe that our multidisciplinary approach can accelerate the drug development and approval process. Our ethos is to always be reliable, proactive and flexible. We aim to be a true partner that provides excellent services.
We want to be a trusted drug development partner for our pharma customers around the world.
By leveraging our expertise, experience, infrastructure, resources, technology and global network, we help our customers to bring innovative drugs to clinics and market efficiently and effectively.
We recognize that speed and excellence are important factors in drug development. To accelerate the drug development and approval process, we rely on an integrated, agile, phase-appropriate and dossier-centric approach.
We have a deep understanding and exceptional experience which we leverage to guide our approach and deliver the best possible outcomes for our partners.
We have carefully invested in or acquired platforms and facilities that are uniquely engineered to support and enable integrated early phase development for our partners’ oral drugs, nanomedicines and injectables.
Idifarma, based in Pamplona, Spain, offers a full range of services spanning the pharma lifecycle from formulation, analytical to manufacturing services for highly potent drugs. Its capabilities include a platform for an accelerated path to clinic and innovating spray drying processes to overcome solubility issues. Established in 2001, Idifarma now has 120 employees.
GHO Capital together with management acquires the Ardena Group from Mentha Capital. GHO plans to further strengthen Ardena’s broad service proposition through organic and inorganic opportunities, adding to both the Company’s offering and international footprint.
Ardena acquires Scandinavian company Syntagon and strengthens its drug substance service offering. Drug substance batch sizes up to 100 kg can be produced. The 30-strong Syntagon team also adds specialist expertise in GMP chromatographic purification processes to our group.
Ardena acquires Chemconnection, adding drug substance and nanomedicine expertise. Based at the Pivot Park life sciences campus in Oss, the Netherlands, ChemConnection employs a team of more than 60 with expertise in process and analytical development, cGMP manufacturing and stability studies for Drug Substances and nanomedicines. Its state-of-the-art facility has the capability to manufacture active ingredients up to 30 kg scale.
Ardena is launched as the new brand for our services. The Ardena name reveals the increased service offering and complementary capabilities of the former companies, Pharmavize and Crystallics. Our logo resembles a compass and symbolizes Ardena’s navigational skills. During the drug development journey, we point, with minimized risk, our customers in the best direction.
The acquisition of Netherlands based ABL broadens our preclinical and clinical offering to include bioanalytical and drug discovery services. The 60-strong ABL team specializes in the analysis of endogenous (biomarkers) and exogenous compounds (drugs) in biological matrices derived from humans and animals. ABL is active in all phases of drug development, including discovery, pre-clinical and clinical phases.
Netherlands based Crystallics is the first company that joins Pharmavize in executing its vertical integration strategy. Crystallics is specialized in the identification, characterization and selection of the physical forms of drug substances. The company is a pioneer in the field of solid-state research and developed unique and proprietary technologies.
Pharmavize, a Belgium based CDMO specialized in drug and dossier development, engages private equity company Mentha Capital and starts executing a M&A strategy to become a leading, one-source and fully integrated contract developer of investigational drugs.
Get in touch to see how we can craft your path to the clinic with dedicated capabilities.